Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

By F. Saad, D. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J. Chin, J. Vinholes, J. Goas, M. Zheng. Journal of the National Cancer Institute, 2004

1,197 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/a821dd09e2461d83e414917269574f45bd6f4e9a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Hallek
2. A. Heidenreich
3. Michel Bolla
4. N. Mottet
5. J. Bellmunt
6. V. Matveev
7. Steven Joniau
8. F. Zattoni

In Pulmonary and Respiratory Medicine

1. M. Hallek
2. A. Heidenreich
3. Michel Bolla
4. N. Mottet
5. J. Bellmunt
6. V. Matveev
7. Steven Joniau
8. F. Zattoni

Citations in the corpus

• Prostate Cancer (2018, background): “Published studies have shown superiority of PCA3 of predicting outcomes of prostate biopsy when compared to PSA [68] and %fPSA [69].”
• EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. (2011, background): “To date, zoledronic acid is the only bisphosphonate that has been shown to reduce both pain and the number of skeletal-related events in CRPC patients with bone metastases compared with placebo [84].”
• Pathologic fractures correlate with reduced survival in patients with malignant bone disease (2007, background): “myeloma, prostate cancer, and lung cancer or other solid tumors.(6,8,15,17) Although correlations between pathologic frac-”
• American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. (2009, background): “IV Bisphosphonates IV bisphosphonates are primarily used and effecive in the treatment and management of cancerelated conditions, including hypercalcemia of maligancy, skeletal-related events associated with bone etastases in the context of solid tumors such as reast cancer, prostate cancer, and lun”